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Current adjuvant treatment guidelines for oropharyngeal squamous cell carcinoma treated with primary surgery are
based on studies that predate the human papillomavirus (HPV) era. HPV-associated oropharynx carcinoma (HPV-OPC) has
a much more favorable prognosis compared to HPV-unassociated cancer and is increasingly considered to be a distinct
disease entity due to its unique etiology, presentation, and behavior. Currently, there is significant interest in adjuvant
treatment de-intensification of HPV-OPC patients in order to reduce treatment-related toxicity while maintaining excellent
clinical outcomes. Here, we review the evidence and rationale underlying the ongoing prospective trials of adjuvant
treatment de-intensification for HPV-OPC patients.
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The incidence of oropharyngeal cancer (OPC) has been
increasing, in contrast to an overall decrease in all head
and neck cancers rates [1, 2]. The rise in incidence of
OPC has been attributed to the human-papillomavirus
(HPV), and HPV-associated oropharyngeal carcinoma
(HPV-OPC) is known to have distinct oncogenesis,
clinical features, treatment response, and prognosis.
Cigarette smoking is not thought to have a causative role
in the development of HPV-OPC and this likely explains
why its rising incidence differs from the overall trend of
head and neck cancers [3]. High-risk HPV strains, pre-
dominantly HPV-16 and HPV-18, cause carcinogenesis
via viral proteins E6 and E7, which inactivate tumor sup-
pressors p53 and Rb, respectively. HPV-OPC is more
likely found in younger males in developed countries
with a limited smoking history and now comprises about
70% of all new oropharynx cancers in the United States
[4]. Clinically, HPV-associated disease tends to present
with smaller primary tumors, larger metastatic lymph
nodes, and with histopathology more likely to have non-
keratinizing, basaloid features and poor differentiation [5].* Correspondence: zain.husain@yale.edu
1Department of Therapeutic Radiology, Yale University School of Medicine,
Smilow Cancer Hospital LL 515, 35 Park St, New Haven, CT 06510, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeEvidence from secondary analyses of randomized
clinical trials studying adjuvant treatments (RTOG 0234
and DKTK-ROG) have demonstrated superior clinical
outcomes in HPV-associated patients treated with sur-
gery and adjuvant chemoradiation [6–8]. For instance,
HPV-OPC in RTOG 0234 had a significantly improved
2-years overall survival (OS) compared to the HPV-
unassociated group (90.9% vs. 40% in cisplatin arm;
100% vs. 66.7% in docetaxel arm) [7]. Additionally, retro-
spective subgroup analyses of key prospective trials of
definitive chemoradiation also show marked better per-
formance of HPV-associated compared to HPV-
unassociated cases (Table 1).
Since HPV-OPC has a more favorable prognosis, treat-
ment de-intensification for HPV-OPC has become a pri-
mary research objective, especially due to concern over
long-term treatment toxicities. Long-term treatment-
related morbidity may be even more impactful for HPV-
OPC patients because of their potential for longer
survival after therapy and younger age at diagnosis.
Concerning treatment-related side effects include
gastrostomy-tube requirement, with 1-year rates ranging
from 4 to 18% after trans-oral surgery [9–11] and
5–10% after definitive chemoradiation with modern
radiation techniques [12]. And even for patients who arele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Select prospective trials that demonstrated improved
outcomes for HPV-associated disease on unplanned retrospective
subgroup analysis
Trial Comparison arms Finding
(HPV+ improved
outcomes)
RTOG 0129 [44] 70 Gy over 7 weeks vs 72 Gy








ECOG 2399 [46] Phase II trial: 2 cycles of
induction paclitaxel/carboplatin




TROG 02.02 [47] Radiation with concurrent





TAX 324 [48] Induction docetaxel/cisplatin/
fluorouracil followed by radiation
with concurrent carboplatin vs.
induction cisplatin/fluorouracil
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significantly decrease quality of life [13, 14].
Main text
Oropharynx carcinoma surgery
Standard management of OPC includes either frontline
surgery or frontline radiation therapy, with or without
concurrent chemotherapy. Frontline surgery includes
not only resection of the primary tumor but also neck
dissection with adjuvant therapy reserved for adverse
pathologic features.
Primary surgery for OPC has experience a renaissance
within the last decade [15]. Traditionally, primary
surgery required an open trans-cervical approach with
potential for considerable morbidity. As such, organ-
preservation with definitive chemoradiation gained
popularity in the 1990s and early 2000s. More recently,
transoral endoscopic head and neck surgery (eHNS) has
emerged as a functional organ preservation approach.
eHNS consists of a minimally-invasive procedure using
miniaturized instrumentation that avoids mandibulot-
omy and external incisions. eHNS is performed with car-
bon dioxide laser microsurgery or robotic surgical
system and has been associated with a resurgence of
primary surgical treatment for T1-T2 OPC [16]. Early
reports have demonstrated that eHNS is associated with
a lower complication rate and faster post-operative
recovery [17, 18]. Moreover, oncologic outcomes from
eHNS appear to be promising. A 2012 meta-analysis of
over 500 OPSCC patients from 17 retrospective eHNSstudies showed 1-year OS of over 90% and 2-year sur-
vival between 80 and 90% [18]. Most patients in this
meta-analysis with standard indications for adjuvant
treatment received adjuvant radiation or chemoradia-
tion. Additionally, the meta-analysis found generally
lower rates of functional deficits after trans-oral surgery,
including a gastrostomy-tube dependence at 1-year of
0–9.5%. Aside from T1-2 disease, eHNS has also been
used for locally-advanced OPSCC with acceptable clin-
ical outcomes, suggesting upfront eHNS for selected
stage III/IV OPC may also be appropriate [9, 19].
Recently, the largest multi-institutional report thus far of
410 head and neck cancer patients treated with eHNS,
89% of which were oropharyngeal primaries, found
2-year and 3-year loco-regional control rates of 91.8 and
88.8% with only 1 surgery-related mortality [20].
Indications for adjuvant therapy
National Comprehensive Cancer Network (NCCN)
guidelines recommend OPC patients after up-front sur-
gery who have distinct adverse pathologic features
receive either adjuvant radiation alone or chemoradia-
tion [21]. Chemoradiation is recommended for high risk
adverse features: extranodal extension (+ENE) and/or
positive surgical margin(s). Other adverse pathologic fac-
tors are typically treated with adjuvant radiation alone.
These are perhaps best summarized by the inclusion cri-
teria of RTOG 0920, a phase III study of adjuvant radi-
ation +/- cetuximab for head and neck squamous cell
carcinoma (HNSCC) patients with intermediate risk
factors. These intermediate risk factors include: close
margin (<5 mm), ≥ 2 metastatic lymph nodes (LN) or a
single LN > 3 cm, perineural invasion (PNI), lymphovas-
cular invasion (LVI), T3 or T4a primary, or patients with
initially focally positive margins but undergo re-excision
with final negative margins. While not an inclusion
criterion of RTOG 0920, nodal involvement of levels IV
or V in oropharynx primary was also included by NCCN
as an “intermediate” risk factor.
The evidence underlying the recommendation for che-
moradiation for patients with high-risk features comes
from two landmark studies, RTOG 9501 and EORTC
22931. In RTOG 9501, chemoradiation improved
2-years loco-regional control (82% vs. 72%, p = .01), and
a disease-free survival benefit (reported HR 0.78), with
the tradeoff of higher grade 3+ toxicity (77% vs. 34%)
[22]. Conversely, EORTC 22931 demonstrated benefit of
chemoradiation for local control (82% vs. 69%, p = .007),
PFS (5-year estimate 47% vs. 36%), and 5-years OS (53%
vs. 40%, p = .02) [23]. The two studies had notably
slightly different inclusion criteria (Table 2). In RTOG
9501, high-risk was defined as 2 or more metastatic LN,
+ENE, or positive surgical margins [24]. Inclusion cri-
teria of EORTC 22931 were more broad and included
Table 2 Inclusion criteria for select randomized adjuvant treatment
trials comparing chemoradiation versus radiation alone
Trial Inclusion criteria
EORTC 22931 [23] Sites: oral cavity, oropharynx, larynx, or hypopharynx
1 of the following:
• pT3-4 N0-3 except for T3N0 of the larynx with
negative resection margins
• pT1-2 N2-3
• pT1-2 N0-1 and positive margins, PNI, or vascular
embolism (lymphovascular invasion)
• oral cavity or oropharyngeal primaries with level
IV or V lymph node involvement
RTOG 9501 [22] Sites: oral cavity, oropharynx, larynx, or hypopharynx
Status post complete macroscopic resection
1 of the following
• two or more metastatic regional lymph nodes
• extracapsular extension
• microscopically involved mucosal margins of
resection
Table 3 Grading system for extranodal extension for metastatic
lymph node established by Lewis et al [49].
Extra Nodal Extension Grading System
Grade Histologic Finding ENE positivity
0 Tumor is surrounded by lymphoid tissue –
1 Tumor reaches the capsule (with no intervening
lymphoid tissue) with thickening
of overlying capsule
–
2 Tumor in perinodal tissue, extending≤ 1 mm
beyond capsule
+
3 Tumor in perinodal tissue and extending
> 1 mm beyond capsule
+
4 Tumor mass without residual nodal tissue or
architecture. No residual lymphoid architecture
or germinal center.
+
Higher grader corresponds with more severe ENE. Grades 0–1 are usually defined
as negative ENE while grades 2–4 are defined as positive ENE. Grade 4 also
designated as Soft Tissue Metastasis
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margins, PNI, or LVI, and oral cavity or oropharyngeal
primary cancers with level IV or V lymph nodes (add-
itional criteria in Table 2). In order to make sense of who
benefits most from chemotherapy, a subsequent combined
analysis of the EORTC 22931 and RTOG 9501 trials and
subsequently found + ENE and positive margins were the
only features that statistically predicted overall survival
benefit with chemoradiation [25].
The prognosis of extranodal extension in HPV-OPC
Given the favorable prognosis of HPV-OPC, the ques-
tion has been raised whether ENE carries the same
adverse prognostic value in this favorable group of pa-
tients. Several concerns arise with applying findings
from RTOG 9501 and EORTC 22931 to HPV-OPC
patients. HPV status testing was not routinely performed
in the two trials. Furthermore, oropharyngeal primaries
made up only 42 and 30% of the RTOG 9501 and ECOG
22931, respectively, suggesting that HPV-OPC made up
a minority of patients in those studies.
Several other issues arise when trying to understand
the prognostic implications of ENE amongst HPV-OPC
patients, not the least of which is there may be signifi-
cant intra- and inter-observer variability in assessing
ENE. In a study from Washington University with 152
patients, slides were re-examined by a single study-
pathologist and the results were compared to the ori-
ginal pathology report. ENE was reported to be present
in 124/152 cases or 82% of cases as read on the initial
pathology reports but only present in 79/152, or only
52%, on re-review [26]. It is troubling that even within a
single high-volume center there can be a thirty percent
discrepancy in pathologic assessment of ENE. In a later
study, the same authors created digitally scanned nodalmetastases slides, which were initially read by five differ-
ent pathologists. These pathologists were instructed to
perform a dichotomous assessment for ENE as either
present or absent, and there was agreement in only 48%
of cases. Subsequently, the pathologists were given a de-
fined system which grades ENE into four categories, and
agreement improved slightly to 64% [27].
This study, in turn, raises another point: while the
seminal studies describing the benefit of chemoradiation
in ENE positive patients graded ENE dichotomously as
present or absent, more recent investigation now sug-
gests the extent of ENE may be better characterized as a
spectrum, and the degree of ENE may matter as well. In
the aforementioned Washington University experience,
the pathology reporting of the presence or absence of
ENE did not correlate with disease-free survival (DFS).
However, when ENE was graded on the four-point sys-
tem, the group with grade 4, defined by the presence of
soft tissue metastasis (STM), had a reduced DFS com-
pared to patients without STM (80% vs 93%, p = .02)
(see Table 3 for their ENE grading system). Taken
together, this suggests that extent of ENE is important to
consider, and not all patients with ENE may have a simi-
lar prognosis. This approach has been adopted in the
ECOG 3311 trial, where patients with ≤ 1 mm of ENE
are enrolled in the radiation alone arm. For patients with
>1 mm, post-operative chemoradiation is given in this
high-risk arm.
Studies have also examined whether ENE in patients
with HPV-OPC is a risk factor for disease-free survival
following surgical resection. In the Washington University
experience of p16+ OPC patients after eHNS, the rate of
DFS was not significantly different amongst patients
whose pathology reports described ENE versus those with-
out, with 3-year disease-specific survival (DFS) estimates
of 89% (95% CI 84–95%) and 94% (95% CI 83–100%),
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study from the University of Pittsburgh that examined 76
patients with HPV-OPC, 45 of which had ENE. There was
no difference in rates of DSS amongst patients with or
without ENE (p = 0.936) [28]. In a subsequent update,
these patients were reported to have a 5-year DSS of
84.8% (95% CI 64.4–94.05%) in patients with ENE and
89.3% (95% CI 73.9–98.1%) in patient without ENE [29].
The most provocative evidence suggesting a lack of
benefit from concurrent chemoradiation for patients
with HPV-OPC comes from retrospective comparisons
of patients with ENE that received either radiation
therapy alone or chemoradiation. In the Washington
University series, 113 patients had ENE graded on their
pathology reports, and, of this group, 48 were treated
with radiation alone while 65 were treated with chemo-
radiation. The 3-year DFS rates were similar at 94.5% in
the radiation group and 91.8% in the chemoradiation
group (p = .74) [26]. These values should of course be
taken with the caveats associated with a single institu-
tion retrospective study, and the results could of course
be reflective of patient selection, but nonetheless it
remains a notable finding.
Taken together, the benefit of chemoradiation in HPV-
OPC patients with ENE remains a pivotal unanswered
question in modern head and neck oncology. The under-
lying recommendation for chemoradiation for ENE posi-
tive patients came from a larger group of HNSCC most
of which were likely not HPV-associated, and therefore
carry a different biology, natural history, and a signifi-
cantly worse prognosis. In addition, the historic dichoto-
mization of ENE may actually be an oversimplification
of the true risk of recurrence, and further efforts are
needed to standardize the reporting of ENE across cen-
ters. The current data, limited to small single institution
series at high volume centers, shows that ENE does not
appear to be necessarily associated with worse disease
specific survival, and that patients who received radi-
ation seemed to do similarly to those who receive
chemoradiation. Given the additional toxicity with che-
moradiation, which is associated with more than double
the rate of grade 3 or higher acute toxicity in compari-
son to radiation alone [22], answering the question of
whether concurrent chemotherapy is necessary for
patients with ENE is a critical priority for the head and
neck oncology community.
Number of positive lymph nodes
Attention has recently been paid to whether patients
with a higher number of pathologically involved lymph
nodes represent a separate high-risk group. A study of
HPV-OPC after eHNS from Washington University
found the presence of five or more involved LN was as-
sociated with a recurrence rate of 24% on multivariableanalysis (OR 3.12) [30]. Additionally, a recent study from
the SEER database demonstrated that oropharyngeal car-
cinoma patients with 5 or more involved lymph nodes
had a worsened survival, although this study was limited
in that information on HPV and p16 testing was unavail-
able [31]. In contrast, the recently proposed staging
system for HPV-OPC, the ICON-S group concluded that
the number of positive lymph nodes was not predictive
of OS, though this was in a group of patients that largely
had clinically as opposed to pathologically staged nodal
disease [32]. ECOG 3311 includes patients with five or
more involved nodes in its high-risk group to receive
adjuvant chemoradiation, and results from this study
should provide needed prospective data about nodal
number and the risks of recurrence [33].
Post-operative radiation dose
There is considerable variation among studies in terms
of radiation dose used in the adjuvant setting, and
whether this should be affected by high risk factors such
as ENE or positive margins. Fortunately, there is ran-
domized data to help provide guidance. Peters et al. per-
formed a Phase III study investigating the optimal
adjuvant radiation dose required based on postoperative
risk stratification. The study included 240 patients, and
nearly all were stage III/IV oral cavity, oropharynx,
hypopharynx, or larynx primaries after initial resection.
Patients were assigned into low-risk or high-risk groups
for both primary site and nodal disease based on a point
system incorporating T-stage, margins status, and nerve
involvement for primary site and nodal number, and
nodal groups for nodal disease. Low risk patients were
randomized to a dose of 57.6 Gy (initially < 54 Gy) vs.
63 Gy, and high-risk patients were randomized to
68.4 Gy vs. 63 Gy. The 2-years loco-regional control rate
for the low risk primary site group was 92% for 57.6 Gy,
89% for 63 Gy, but only 63% for <54 Gy. This led the au-
thors to conclude 57.6 Gy in 1.8 Gy fractions was the
recommended dose for postoperative patients with inter-
mediate risk factors. In the high-risk group, 2-year local
control was 89% with 63 Gy and 81% with 68.4 Gy.
There was a noticeable local control dose-response in
the subgroup of ENE+ cases, as among ENE+ cases, the
2-years control rate was 52% for 57.6 Gy, 74% for 63 Gy,
and 72% for 68.4 Gy [34]. With these findings, the rec-
ommended postoperative radiation dose for ENE+ pa-
tients was 63 Gy in 1.8 Gy fractions. Interestingly a
similar dose response was not seen for patients with
positive margins. Despite this level 1 evidence, these
doses were never widely adopted. Practitioners have
largely moved to using a daily dose of at least 2 Gy per
day, given data that showed a benefit to shorter
treatment courses [35, 36]. Using the linear quadratic
equation, 57.6 Gy in 1.8 Gy fractions translates to
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1.8 Gy fractions translates to approximately 62 Gy in
2 Gy fractions. Perhaps for reasons more logistical than
scientific, this has often translated to a dose of 60 Gy to
areas of potential microscopic disease, with some push-
ing for a boost to areas of ENE or positive margins to
66 Gy. This variation is seen even among large coopera-
tive group trials. Current studies of intermediate risk
patients, such as RTOG 0920, and the standard arm of
ECOG 3311 use a dose of 60Gy. For high-risk patients,
RTOG 9501 mainly used 60 Gy though 13% received an
optional 6 Gy boost while EORTC 22931 mainly used
66 Gy. The current high-risk study for p16(-) cancers,
RTOG 1216, calls for 60 Gy with an optional 6 Gy boost
given concurrently. ECOG 3311, which is limited to p16
positive patients, uses 66 Gy in its high-risk arm. This
variation is reflected in national practice guidelines
which call for a dose to high-risk sites (positive margins
and/or + ENE) of 60–66 Gy in 2 Gy fractions and a dose
to intermediate risk sites of 54–63 Gy using simultaneous
dosing techniques [21]. Recent evidence, however, sug-
gests a lack of benefit for higher doses in HPV-associated
oropharyngeal cancer. Investigators at Washington
University compared outcomes for patients with HPV-
associated OPSCC and the risk factors of close or positive
margins and/or ECE, but treated to different radiation
doses [37]. The institutional standard dose for such
patients was 66 Gy from 1998 to 2009 but was changed to
60 Gy in 2009. Researchers found no significant differ-
ences in 2-year loco-regional recurrence-free survival,
cause-specific survival or overall survival between 60 Gy
and 66 Gy groups, suggesting 60Gy may be a reasonable
adjuvant radiation dose in HPV-associated OPSCC.
Omitting adjuvant radiation to the primary tumor bed
Another potential de-intensification approach is consid-
eration of omitting adjuvant radiation to the primary
tumor bed. The rationale here is that given the improved
margin control of eHNS and low rates of tumor bed
recurrence seen in early stage patients who are observed
after eHNS, primary site irradiation may not be neces-
sary. The indication for irradiation in many early stage
patients ends up being the presence of multiple involved
lymph nodes, and thus it is hypothesized that perhaps,
the neck alone can be irradiated, translating to smaller
radiation volumes and potentially less morbidity.
A recently published study of p16+ oropharyngeal
SCC patients after eHNS found a local recurrence rate
of only 3% (3/92) in pT1-T2 patients who did not
receive adjuvant radiation to the primary tumor bed,
although approximately half did receive neck directed
irradiation [38]. Those spared adjuvant RT to the pri-
mary bed were also found to have lower gastrostomy
tube rates (10% vs 2% 1-year rate for pT1-T2). Theauthors concluded their findings suggest that omitting
primary tumor adjuvant radiation in low-risk, early T-
stage, HPV-associated oropharyngeal carcinoma patients
appears safe and may be associated with less functional
morbidity.
Of note, while in theory eliminating the primary tumor
bed as a target would theoretically lead to a substantial
decrease in radiation to normal tissues, dosimetric stud-
ies comparing primary plus neck irradiation with neck-
only irradiation suggest only a modest potential benefit
with this approach [39, 40]. This may be due to the fact
that the level II lymph nodes, which represent the first
echelon nodal drainage for oropharyngeal cancers, and
are thus always in the neck radiation volume, sit adja-
cent to the tonsil and base of tongue. An dosimetric
analysis of radiation for tonsillar cancer patients com-
pared tonsil/post-operative bed doses for patients treated
to the unilateral neck only, and found that the primary
site still received a mean dose of 53.9 Gy [39]. Addition-
ally, the radiation dose to bilateral parotid glands, larynx
or mandible was not significantly lower in the neck-only
radiation treatment plans. There was however a slight
benefit in dose to the oral cavity (34.0 Gy vs. 29.8 Gy
p = 0.002) and superior pharyngeal constrictors (46.1 Gy
vs. 42.9 Gy p = 0.01). A separate study of base of tongue
tumors compared radiation plans of patients receiving
adjuvant radiation to the bilateral neck and primary tumor
to those same patients replanned to receive only bilateral
neck radiation and found a decrease in oral cavity dose
(47.4 Gy vs. 22.3 Gy) but no significant benefit for contra-
lateral parotid or pharyngeal constrictor muscles [40]. Of
note, the primary tumor bed still received a mean dose of
40.2 Gy, which could complicate consideration of future
re-irradiation for any patients who may recur.
Currently, a University of Pennsylvania phase-II trial is
underway that will further elucidate the benefits of neck
only irradiation in HPV-associated OPSCC patients after
eHNS (NCT02159703). The ADEPT adjuvant trial will
also allow omission of primary bed radiation in pT1-2
patients with a negative surgical margin who still have
an indication for neck irradiation (NCT01687413).
Current treatment de-intensification trials with primary
surgery in HPV-OPC
Several ongoing trials are analyzing treatment de-
intensification in the adjuvant setting, and are summa-
rized in Table 4. Below is a discussion of some of the
larger trials. ECOG 3311 stratifies patients into three
risk groups. The low risk group requires negative mar-
gin, 0–1 involved LN, and negative ENE, and do not
receive any adjuvant therapy. The intermediate risk
group, which includes negative margin but ≤1 mm ENE
or 2–4 involved LN, is randomized to receive either
standard adjuvant radiation of 60 Gy or de-escalated
Table 4 Active Phase II/III Trials of Surgically-treated HPV-OPC
Trial Details Inclusion Criteria Stratify Definition Treatment












Randomized: 50 in 25 fx Gy vs




66 Gy with weekly cisplatin
(40 mg/m2 weekly)






None Randomized: 60 Gy +/- cisplatin
(40 mg/m2 weekly)











• Close margins (1–5 mm)
Randomized: 50 Gy in 25 fx vs
60 Gy in 30 fx
High Positive margin (<1 mm)
Negative marginal biopsy
+ENE
Randomized: 60 Gy +/- cisplatin
(40 mg/m2 weekly)
















Matted or SCV nodes
56 Gy with cisplatin (40 mg/m2
weekly)
Mayo Clinic [41] Phase II Post-surgery
Stage I-IVB
R0 resection
At least one of following:








36 Gy in 20 fractions








• Positive or microscopically positive surgical
margins (negative or close (<2 mm) margins
of primary cancer
• PNI of primary cancer
All trial patients forgo adjuvant
radiotherapy to the primary
cancer
R0 negative surgical margin, R1/R2 positive surgical margin, PNI perineural invasion, LVI lymphovascular invasion, ENE extranodal extension, LN+ involved lymph
nodes, SCV nodes supraclavicular lymph nodes
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margin, >1 mm or ≥ 4 involved LN, invariably receive
66 Gy with concurrent cisplatin, which is in line with
standard treatment recommendations.
The PATHOS trial, funded by Cancer Research UK, is
similar to ECOG 3311 since it also calls for post-eHNS
stratification into low, intermediate, and high-risk groups.
However, the PATHOS trial employs different criteria for
intermediate and high-risk groups. Intermediate-risk
inclusion criteria are: negative margin, at least pT3 diseaseor pT1-2 disease with pN2a/b, PNI, LVI, or close margin
(defined as 1–5 mm). Intermediate risk patients are
randomized to standard arm of 60 Gy in 30 fractions or
dose-de-escalated to 50 Gy in 25 fractions. The high-risk
group requires positive margins or + ENE, and these
patients are randomized to 60 Gy with cisplatin or without
concurrent chemotherapy.
Similar to the PATHOS high-risk arm, the ADEPT
phase III trial will also elucidate if adjuvant chemother-
apy is needed for HPV-OPC patients with + ENE. Closed
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with + ENE but negative surgical margins. Patients are
randomized to the standard 60 Gy with concurrent cis-
platin or de-intensified to 60 Gy without chemotherapy.
Additionally, a single-arm Mayo Clinic phase II trial
underway is studying the use of an accelerated hyper-
fractionated twice daily (BID) radiation in post-operative
cases [41]. The radiation schedule consists of 36 Gy in
20 fractions in 1.8 Gy BID dosing and delivered 5 days a
week within the first 12 days with concurrent docetaxel.
This reduced radiation dosing is inspired by studies
showing lower doses were able to control disease in anal
cancer, another HPV-associated squamous cell carcin-
oma [42]. Eligible patients must have at least one of the
following risk factors: LN > 3 cm, two or more meta-
static LN, perineural invasion, LVSI, pT3, or microscopic
pT4a stage.
Finally, there is also an ongoing University of Pennsylva-
nia single-arm phase II trial of pT1-T2, N2a-c patients
after eHNS who receive adjuvant radiation only to the
neck and not the primary tumor bed [43]. This study ad-
dresses the question can the primary tumor bed forgo ad-
juvant radiation and potentially reduce toxicity if the only
indication for adjuvant irradiation is multiple involved
neck nodes (without risk factors at the primary site) [43].
Conclusions
The superior prognosis of HPV-OPC has catalyzed
clinical investigation of treatment de-intensification.
Ongoing phase II and phase III trials will provide novel
risk-adjusted adjuvant treatment schemes and provide
answers regarding the appropriateness of radiation dose
reduction or reduction of systemic therapy in HPV-
OPC. These studies will also answer if traditional
adverse post-operative risk factors, such as + ENE or
positive margins, have the same prognostic value as in
HPV-associated cohort. It should be noted, however,
that therapeutic de-escalation is a hypothesis requiring
clinical study - at this time HPV-OPC patients should
continue to receive standard of care adjuvant treatment
according to national guidelines unless on a clinical trial.
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